A phase IIb multicentre trial in the UK is further evaluating the effects of liraglutide in mild to moderate AD at 12 months (ELAD, NCT01843075)66: a preliminary analysis in 204 patients showed better cognitive function measured on the Alzheimers Disease Assessment Scale-Executive Domain scale,30 and an update presented at the Alzheimers Association International Conference in 2024 revealed that this medication significantly reduced cognitive decline by 18% compared with placebo, even though this was a secondary outcome which should therefore be interpreted cautiously.67 A large phase III trial (evoke/evoke+) assessing the efficacy, safety and tolerability of oral semaglutide over 3 years, along with informative plasma and CSF biomarkers, in early-stage symptomatic AD is ongoing and expected to be completed in September 2025.68 While these results are pending, the paucity of evidence from randomised data in small samples of patients should be interpreted cautiously
But its always worth keeping an eye on things and speaking to your healthcare provider if you notice: Persistent or painful urination Recurrent UTIs Any blood in your urine A significant change in how often you're peeing These symptoms could point to something unrelated to Mounjaro, but still worth checking out
In short, non-arteritic anterior ischemic optic neuropathy, which is possibly linked to Ozempic, can cause permanent blindness/vision loss in one eye
As more data has become available, scientists have taken a closer look at how GLP-1 receptor agonists affect the brain
gutbrain axis
.jpg)
